Y. Tadayasu

Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.

M. Takano, A. Sarashina, A. Staab, 2013, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

M. Bando, Y. Sugiyama, Y. Kondoh, 2014, European Respiratory Journal.

Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease

C. Kunz, Y. Fukuchi, M. Ichinose, 2015, International journal of chronic obstructive pulmonary disease.

Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment

H. Ueno, K. Muro, M. Ikeda, 2016, Cancer science.

Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.

S. Higuchi, A. Sarashina, I. Ieiri, 2010, British journal of clinical pharmacology.

Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD.

Zhenlei Wang, Y. Tadayasu, Chao Hu, 2020, Pulmonary pharmacology & therapeutics.